Subcutaneous injections do not require a port like an IV, eliminating the risk for port-related complications such as infections.

Mohammady M et al (2017) Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity. Cochrane Database of Systematic Reviews; 10: CD008077. Ogston-Tuck S (2014 ...

What if you could inject a drug into a "problem area" – like abdominal fat – that could kill off fat cells and reduce fat ...

Ocrevus subcutaneous injection was non-inferior to Ocrevus IV infusion as measured by Ocrevus levels in the blood of patients (area under the serum concentration time curve) from day 1 to 12 weeks ...

Further, pharmacokinetic modeling predicts that convenient dosing regimens of VRDN-003 (e.g., a low volume subcutaneous injection once every 4 or 8 weeks) could achieve exposure levels of VRDN-003 ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase ...

A new kind of HIV prevention is making it easier for those at risk to stay protected, thanks to a twice-yearly injection now ...

BD (Becton, Dickinson and Company) announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics.

Researchers have found in ALPACA trial that Lepodisiran demonstrated a substantial reduction in lipoprotein(a) levels, ...

FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis Published Sep 16, 2024 1:00am EDT ...

Argenx took a big step toward adding a subcutaneous option on Tuesday with the delivery of top-line data from a trial that compared its investigational formulation to the approved intravenous ...